AstraZeneca Pharma India Ltd has received authorization to import and sell Trastuzumab Deruxtecan (Enhertu) for an additional indication in India, specifically for adult patients with HER2-positive solid tumors. This approval allows for marketing of the product, pending further statutory approvals.